澤璟製藥(688266.SH):子公司香港澤璟擬收購GENSUN經完全攤薄後4%股份
格隆匯1月19日丨澤璟製藥(688266.SH)公佈,為履行公司首次公開發行股票並上市時關於消除潛在利益衝突的承諾,公司的全資子公司Zelgen Holdings Limited(澤璟控股有限公司,簡稱“香港澤璟”)擬與JACKIE ZEGI SHENG(盛澤琪)、MIKE C SHENG、Gensun Biopharma Inc.(簡稱“GENSUN”)簽訂《關於璟尚生物製藥公司股份購買協議》,以合計361.12萬美元收購JACKIE ZEGI SHENG(盛澤琪)、MIKEC SHENG 合計持有的GENSUN 255,554股股份(分別收購JACKIE ZEGI SHENG(盛澤琪)、MIKE C SHENG 各自持有的127,777股股份),即合計對應GENSUN經完全攤薄後4%的股份,收購資金來源為自有資金。
上述交易完成後,公司將通過香港澤璟間接持有GENSUN經完全攤薄後55.74%股份。
公司的全資子公司香港澤璟擬與JACKIE ZEGI SHENG(盛澤琪)、MIKEC SHENG、GENSUN簽訂《關於璟尚生物製藥公司之協議書》,約定在《協議書》生效後三年內,香港澤璟有權利按照GENSUN整體估值即9027.93萬美元(《股份購買協議》項下約定的GENSUN整體估值)計算得出的購買價格收購JACKIE ZEGI SHENG(盛澤琪)、MIKE C SHENG屆時擁有的GENSUN全部發行在外的股份(“購買選擇權”)。香港澤璟有權以其認為適當的方式多次部分地或一次性全部地行使購買選擇權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.